Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Adams, Richard A.; Fisher, David J.; Graham, Janet; Seligmann, Jenny F.; Seymour, Matthew; Kaplan, Richard; Yates, Emma; Parmar, Mahesh; Richman, Susan D.; Quirke, Philip; Butler, Rachel; Brown, Ewan; Collinson, Fiona; Falk, Stephen; Wasan, Harpreet; Shiu, Kai-Keen; Middleton, Gary; Samuel, Leslie; Wilson, Richard H.; Brown, Louise C.; Maughan, Timothy S.; FOCUS Trial Collaboration

Citation

Adams , R A , Fisher , D J , Graham , J , Seligmann , J F , Seymour , M , Kaplan , R , Yates , E , Parmar , M , Richman , S D , Quirke , P , Butler , R , Brown , E , Collinson , F , Falk , S , Wasan , H , Shiu , K-K , Middleton , G , Samuel , L , Wilson , R H , Brown , L C , Maughan , T S & FOCUS Trial Collaboration 2021 , ' Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial ' , Journal of Clinical Oncology , vol. 39 , no. 33 , JCO.21.01436 , pp. 3693-3704 . https://doi.org/10.1200/JCO.21.01436